Tolerance of Bupropion SR After Delayed-Onset Urticaria and Angioedema Associated With Bupropion XL.
Journal
Case reports in psychiatry
ISSN: 2090-682X
Titre abrégé: Case Rep Psychiatry
Pays: United States
ID NLM: 101583308
Informations de publication
Date de publication:
2024
2024
Historique:
received:
16
07
2024
accepted:
08
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Bupropion is an atypical antidepressant indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and smoking cessation. It is also used off-label for attention deficit hyperactivity disorder (ADHD). Its mechanism of action includes the selective norepinephrine and dopamine reuptake inhibitor (NDRI). The drug is available in immediate-release (IR), sustained-release (SR), and extended-release (XL) formulations. Common side effects are typically mild and include anxiety, insomnia, headache, dizziness, constipation, and nausea. Rarely, cutaneous hypersensitivity reactions may occur. We describe a 23-year-old man who developed severe and diffuse urticaria and angioedema 4 weeks after initiation of bupropion XL for MDD and ADHD. The bupropion was stopped, and he was treated with levocetirizine, diphenhydramine (oral and topical), and methylprednisolone with complete resolution of his symptoms within 2 weeks. Due to a good initial therapeutic response to the medication, a trial of bupropion SR was initiated. The patient again had a favorable therapeutic response without any dermatologic side effects.
Identifiants
pubmed: 39478846
doi: 10.1155/2024/6638911
pmc: PMC11524701
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
6638911Informations de copyright
Copyright © 2024 Faisal R. Elali and Arthur C. Grant.
Déclaration de conflit d'intérêts
Dr. Grant is an employee of and Mr. Elali is a medical student at SUNY Downstate Health Sciences University.